lamivudine has been researched along with threonine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lloyd, RM; North, TW; Remington, KM; Schinazi, RF; Smith, RA | 1 |
| Back, NK; Berkhout, B; Boucher, CA; Keulen, W; van Wijk, A | 1 |
2 other study(ies) available for lamivudine and threonine
| Article | Year |
|---|---|
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Topics: Animals; Antiviral Agents; Binding Sites; Cats; Cell Line; Drug Resistance, Microbial; Emtricitabine; Immunodeficiency Virus, Feline; Lamivudine; Methionine; Mutagenesis, Site-Directed; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Threonine; Viral Plaque Assay; Zalcitabine | 1997 |
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Anti-HIV Agents; Genetic Variation; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Threonine | 1997 |